Clinical trials: Non-small Cell Lung Cancer Unresectable
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Lung cancer is the leading cause of cancer-related death in the United States.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal
- Trial name
- NCT03233724
- Testing
- Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Stage III Lung Cancer
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
Multi-center observational clinical study to evaluate the application value of ctDNA monitoring in efficacy assessment and relapse prediction in patients diagnosed with unresectable, locally advanced NSCLC receiving CRT with or…
- Conditions
- Lung Cancer, Stage III Lung Cancer, Unresectable Lung Carcinoma
- Trial name
- NCT05641870
- Testing
- Sample collection, Characterization of the tumoral tissue genomic alterations, Chemoradiation treatment regimen and maintenance (if amenable)
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Parc de Salut Mar
Carcinoma, Non-Small Cell Lung
Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC
This is an open label, multi-center, randomized, control phase III trial, to compare the efficacy and safety of consolidation therapy with sintilimab (IBI308) versus best supported care (BSC), in unresectable stage III NSCLC…
- Trial name
- CONSIST (NCT03884192)
- Testing
- Consolidation Sintilimab
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Shandong Cancer Hospital and Institute
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00032032
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 51 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue…
- Trial name
- NCT04204928
- Testing
- pralsetinib (BLU-667)
- Sponsor
- Blueprint Medicines Corporation
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous…
- Trial name
- NCT01333007
- Where
- 152 sites in France
- Volunteers
- 423 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
The current standard of care for unresectable locally advanced non-small-cell lung cancer (NSCLC) is a combination of chemotherapy and thoracic radiotherapy (TRT).
- Trial name
- NCT02407366
- Testing
- Icotinib, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
NSCLC, Non-small-cell Lung Carcinoma
A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
Durvalumab was approved in the Russian Federation for use after both concurrent and subsequent CRT until disease progression. Currently, there is no real-world data regarding the safety and real world effectiveness of durvalumab…
- Trial name
- NIS durvalumab (NCT05456867)
- Where
- 22 sites in Russia
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation…
- Conditions
- Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
- Trial name
- NCT04789486
- Testing
- AGuIX, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer
ctDNA as a Biomarker for Treatment in Advanced NSCLC
The dynamic monitoring of circulating tumor DNA aims to evaluate the response and progression-free survival of short-course chemotherapy (2 cycles) combined with immunotherapy in patients with locally advanced unresectable or…
- Trial name
- NCT05486988
- Testing
- Immunotherapy, Chemotherapeutic Agent, Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fuzhou General Hospital
Non-Squamous Non-Small Cell Lung Cancer
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
This single arm study will assess the feasibility of use, safety and tolerability of Avastin(bevacizumab) in combination with chemoradiation therapy in patients with locally advanced unresectable non-squamous non-small cell lung…
- Trial name
- NCT00773188
- Testing
- bevacizumab [Avastin], cisplatin, vinorelbine
- Where
- 4 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Non-Small Cell Lung Cancer
Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The aim of this study is to evaluate if the multi modality treatment pemetrexed combined with cisplatin and radiotherapy can lead to a better tumor control and/or a better side-effect profile in patients with locally advanced…
- Trial name
- PACCORA (NCT00497315)
- Testing
- combination chemotherapy (pemetrexed + cisplatin), thoracic irradiation + pemetrexed
- Where
- 3 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- University Hospital, Antwerp
Esophageal Cancer, Lung Cancer
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable…
- Conditions
- Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Trial name
- NCT00019825
- Testing
- decitabine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Unresectable Stage III NSCLC
Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%.
- Trial name
- R-helper (NCT04161352)
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
NSCLC (Advanced Non-small Cell Lung Cancer)
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
This is a randomized, controlled, multicenter clinical study that enrolled patients with unresectable bulky stage III NSCLC, with PFS as the primary endpoint.
- Trial name
- NCT07560358
- Testing
- After chemoimmunotherapy induction, followed by concurrent/sequential chemoradiotherapy and subsequent immune consolidation and maintenance therapy., adebrelimab,Radiation Therapy,Radiotherapy
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally-Advanced Non-Small Cell Lung Cancer, Radiotherapy
Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC
This is a single-center, prospective, open-label, single-arm phase I exploratory study designed to evaluate the safety and feasibility of a novel central immune-priming radiotherapy strategy in patients with unresectable stage…
- Trial name
- NCT07523464
- Testing
- Centrally Confined 8 Gy/1 Fraction Immune-Priming Radiotherapy to the Tumor Core Followed by Definitive Concurrent Chemoradiotherapy
- Volunteers
- 24 people
- Sponsor
- Anhui Provincial Hospital
Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC
Expanded Access of Sotorasib
The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer…
- Conditions
- Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
- Trial name
- NCT04667234
- Testing
- AMG 510
- Where
- 55 sites in United States, Argentina and 4 more
- Sponsor
- Amgen
Non-small Cell Lung Cancer (NSCLC) Stage III
Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Phase Ib study investigating whether liposome BLP25 mucin-1 (MUC1) peptide-specific immunotherapy (L-BLP25) administered as weekly subcutaneous doses over 8 weeks following a single dose of intravenous cyclophosphamide (CPA)…
- Trial name
- FINGERPRINT (NCT01731587)
- Testing
- Biological: MUC1 peptide specific immunotherapy, Cyclophosphamide (CPA)
- Sponsor
- Merck KGaA, Darmstadt, Germany